Loading clinical trials...

Neural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder | Clinical Trials | Clareo Health

WITHDRAWNPHASE4

Neural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder

A Multimodal Brain Imaging Study to Investigate Neural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder: Glycogen Synthase Kinase 3β Single Nucleotide Polymorphisms and Gray Matter Volume Increase Following Lithium Treatment in Bipolar Disorder

NCT01543724•Ewha Womans University

View on ClinicalTrials.gov

Summary

The investigators will assess Li-induced gray matter volume changes with regard to the endophenotype of GSK3beta polymorphism. The changes of gray matter are supposed to be more attributable to neurotrophic and neuroprotective characteristics of Li, which were closely related to the inhibition of apoptotic activity of GSK3beta.

Eligibility

Age

19 - 55 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Men and Women aged between 19 and 55
•Diagnosis of bipolar I disorder as assessed by the structured clinical interview for DSM-IV (SCID-IV)
•Patients who have not used psychoactive medications for more than 2 weeks
•Individuals who provided written consent for participation

Exclusion Criteria

•Presence of any major physical or neurological illness (e.g., head trauma, epilepsy, seizure, stroke, cerebral tumor, multiple sclerosis, cerebrovascular disease, narrow-angle glaucoma, drug hypersensitivity, etc.)
•Women who are pregnant, breastfeeding, or planning pregnancy
•Diagnosis of any Axis I disorder other than bipolar disorder
•Intelligence quotient below 80
•Current or past drug abuse
•Contraindications to magnetic resonance imaging (e.g., pacemaker implantation, claustrophobia, etc.)

Locations (1)

Seoul National University Hospital

Seoul, South Korea

Key Dates

Start Date

June 1, 2015

Primary Completion Date

December 31, 2017

Completion Date

December 31, 2017

Last Updated

February 9, 2018

Conditions

Bipolar Disorder

Interventions

Lithium

DRUG

University of Iowa Interventional Psychiatry Service Patient Registry

NCT04480918

Treatment Resistant DepressionMajor Depressive Episode+5 more

View study

RECRUITINGPHASE3

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

NCT07140913

ManiaBipolar Disorder

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 9, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Neural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder

Inclusion Criteria

Exclusion Criteria

University of Iowa Interventional Psychiatry Service Patient Registry

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Epigenetic Enhancement of Cognitive Training in Aging Mood Disorder Populations

CBT-CP for Veterans With SMI

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Early Intervention for Youth at High Risk for Bipolar Disorder